CL2016003074A1 - Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. - Google Patents

Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.

Info

Publication number
CL2016003074A1
CL2016003074A1 CL2016003074A CL2016003074A CL2016003074A1 CL 2016003074 A1 CL2016003074 A1 CL 2016003074A1 CL 2016003074 A CL2016003074 A CL 2016003074A CL 2016003074 A CL2016003074 A CL 2016003074A CL 2016003074 A1 CL2016003074 A1 CL 2016003074A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
ylacetamide
thiadiazol
ylamino
pyrrolidin
Prior art date
Application number
CL2016003074A
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Chukuemeka Tennyson Ekwuru
Mark David Charles
Piotr Antoni Raubo
Jonathan James Gordon Winter
Johannes Wilhelmus Maria Nissink
Original Assignee
Astrazeneca Ab
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Cancer Research Tech Ltd filed Critical Astrazeneca Ab
Publication of CL2016003074A1 publication Critical patent/CL2016003074A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DERIVADOS DE 2-OXI-2-FENIL-N-5-PIRROLIDIN-3-ILAMINO-1,3,4-TIADIAZOL-2-ILACETAMIDA, INHIBIDORES GLS1 COMPOSICIÓN FARMACÉUTICA Y SU USO PARA TRATAR EL CÁNCER.
CL2016003074A 2014-05-30 2016-11-29 Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. CL2016003074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1409624.2A GB201409624D0 (en) 2014-05-30 2014-05-30 1,3,4-thiadiazole compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CL2016003074A1 true CL2016003074A1 (es) 2017-04-28

Family

ID=51214473

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003074A CL2016003074A1 (es) 2014-05-30 2016-11-29 Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.

Country Status (40)

Country Link
US (2) US10040788B2 (es)
EP (1) EP3148994B1 (es)
JP (1) JP6538830B2 (es)
KR (1) KR20170005875A (es)
CN (1) CN106795150B (es)
AP (1) AP2016009578A0 (es)
AR (1) AR100694A1 (es)
AU (1) AU2015265703B2 (es)
BR (1) BR112016028002B1 (es)
CA (1) CA2949598C (es)
CL (1) CL2016003074A1 (es)
CR (1) CR20160558A (es)
CY (1) CY1120836T1 (es)
DK (1) DK3148994T3 (es)
DO (1) DOP2016000308A (es)
EA (1) EA030937B1 (es)
ES (1) ES2688396T3 (es)
GB (1) GB201409624D0 (es)
GT (1) GT201600250A (es)
HR (1) HRP20181490T1 (es)
HU (1) HUE039879T2 (es)
IL (1) IL249020B (es)
LT (1) LT3148994T (es)
MX (1) MX2016015738A (es)
MY (1) MY192861A (es)
NI (1) NI201600176A (es)
NZ (1) NZ726790A (es)
PE (1) PE20170148A1 (es)
PH (1) PH12016502394A1 (es)
PL (1) PL3148994T3 (es)
PT (1) PT3148994T (es)
RS (1) RS57876B1 (es)
SG (1) SG11201609880QA (es)
SI (1) SI3148994T1 (es)
SM (1) SMT201800516T1 (es)
SV (1) SV2016005330A (es)
TN (1) TN2016000511A1 (es)
TW (1) TWI693220B (es)
UY (1) UY36145A (es)
WO (1) WO2015181539A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520959D0 (en) * 2015-11-27 2016-01-13 Astrazeneca Ab And Cancer Res Technology Ltd Bis-pyridazine compounds and their use in treating cancer
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 １，３，４-噻二唑化合物及其在治療癌症中之用途
US9938265B2 (en) 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
US10323028B2 (en) * 2015-11-30 2019-06-18 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
CN110741003B (zh) * 2017-06-13 2021-07-23 南京明德新药研发有限公司 作为gls1抑制剂的化合物
JP2019064976A (ja) * 2017-10-03 2019-04-25 国立大学法人 熊本大学 抗がん剤
ES2939506T3 (es) 2018-10-16 2023-04-24 Medshine Discovery Inc Derivado de tiadiazol y usos del mismo como inhibidor de GLS1 para el tratamiento de cáncer
ES3010507T3 (en) * 2019-03-05 2025-04-03 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
KR20260022308A (ko) * 2023-05-10 2026-02-19 리얼 테라퓨틱스, 인크. 글루타미나제의 소분자 억제제
CN116854582B (zh) * 2023-07-10 2025-08-29 泰州葛林美克医药科技有限公司 一种对映纯α-甲氧基苯乙酸的制备方法
CN117003745B (zh) * 2023-07-20 2024-06-07 南京市第一医院 Gls1/hdac双靶点抑制剂及其合成方法和应用
WO2025196446A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors
WO2025196447A1 (en) 2024-03-22 2025-09-25 Sitryx Therapeutics Limited Thiadiazoles as glutaminase 1 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288956A1 (en) * 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
WO2012170664A2 (en) 2011-06-10 2012-12-13 President And Fellows Of Harvard College Methods of cancer treatment and prevention through the modulation of sirt4 activity
CN108785305B (zh) * 2011-11-21 2021-10-29 卡利泰拉生物科技公司 谷氨酰胺酶的杂环抑制剂
EP2895623B1 (en) * 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
HUE056078T2 (hu) 2012-11-16 2022-01-28 Calithera Biosciences Inc Heterociklusos glutamináz inhibitorok
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
HK1220640A1 (zh) 2012-12-03 2017-05-12 Calithera Biosciences, Inc. 用谷氨醯胺酶的杂环抑制剂治疗癌症

Also Published As

Publication number Publication date
UY36145A (es) 2016-01-08
DOP2016000308A (es) 2017-03-15
GB201409624D0 (en) 2014-07-16
BR112016028002B1 (pt) 2022-09-27
SMT201800516T1 (it) 2018-11-09
PT3148994T (pt) 2018-10-22
TWI693220B (zh) 2020-05-11
DK3148994T3 (en) 2018-10-08
IL249020B (en) 2020-11-30
NZ726790A (en) 2017-11-24
MX2016015738A (es) 2017-02-27
GT201600250A (es) 2019-06-10
HUE039879T2 (hu) 2019-02-28
TN2016000511A1 (en) 2018-04-04
CN106795150B (zh) 2019-10-15
AU2015265703B2 (en) 2017-12-07
SG11201609880QA (en) 2016-12-29
US20180305349A1 (en) 2018-10-25
LT3148994T (lt) 2018-11-26
PL3148994T3 (pl) 2019-04-30
KR20170005875A (ko) 2017-01-16
SI3148994T1 (sl) 2018-12-31
HRP20181490T1 (hr) 2019-01-11
IL249020A0 (en) 2017-01-31
TW201609720A (zh) 2016-03-16
ES2688396T3 (es) 2018-11-02
EP3148994A1 (en) 2017-04-05
CR20160558A (es) 2017-09-01
PH12016502394A1 (en) 2017-02-20
EA030937B1 (ru) 2018-10-31
EA201692260A1 (ru) 2017-06-30
CY1120836T1 (el) 2019-12-11
NI201600176A (es) 2017-08-25
CN106795150A (zh) 2017-05-31
JP6538830B2 (ja) 2019-07-03
AU2015265703A1 (en) 2016-12-15
EP3148994B1 (en) 2018-07-11
CA2949598A1 (en) 2015-12-03
US10294221B2 (en) 2019-05-21
AR100694A1 (es) 2016-10-26
RS57876B1 (sr) 2018-12-31
WO2015181539A1 (en) 2015-12-03
SV2016005330A (es) 2017-06-07
US10040788B2 (en) 2018-08-07
PE20170148A1 (es) 2017-04-05
AP2016009578A0 (en) 2016-11-30
US20170197954A1 (en) 2017-07-13
BR112016028002A2 (es) 2017-08-22
CA2949598C (en) 2022-08-09
JP2017516859A (ja) 2017-06-22
MY192861A (en) 2022-09-13

Similar Documents

Publication Publication Date Title
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2015002932A1 (es) Inhibidores de proteína quinasa
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
JO3512B1 (ar) مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
CL2015002897A1 (es) Inhibidores de bace1
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
EA201791454A1 (ru) Лекарственные формы для трансдермального введения